Proteome Sciences PLC Completion of new facility in San Diego (2683Y)

TIDMPRM

RNS Number : 2683Y

Proteome Sciences PLC

02 January 2024

2 January 2024

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Completion of new facility in San Diego

Proteome Sciences is pleased to announce the completion of installation and setup of equipment in its new US laboratory in San Diego, California. and is therefore now fully operational. The laboratory uses the latest generation Orbitrap Ascend Tribrid mass spectrometry and automated sample preparation platforms that will extend the range of services offered to customers.

This new facility is based in one of the largest biotech hubs in the US - a hub which has had, collectively, investment of $17.2 bn and US National Institute of Health funding of $6bn in 2022/23 - Proteome Sciences' state of the art Laboratory is well placed to serve demand from a growing number of US customers looking to outsource proteomics projects to underpin their drug development programmes. By removing the need to ship samples internationally our services are more attractive to customers from both Pharma and academia alike.

Dr. Ian Pike, President of Proteome Sciences US Inc, commented "I am delighted that we are able to open our doors to serve arguably the world's largest biotechnology hub in California. Providing easier access to our US customers and with innovations including TMTpro 32plex and single cell proteomics (SCP), delivered from both our dedicated laboratories in the US and Europe we are well set to continue our leading role in provision of tools, assays and services in proteomics research as it grows in importance to enhance pharmaceutical research and drug development."

For further information:

 
 
   Proteome Sciences plc 
 Dr. Mariola Soehngen, Chief Executive        Tel: +44 (0)20 7043 2116 
  Officer 
  Dr. Ian Pike, Chief Scientific Officer 
 Richard Dennis, Chief Commercial Officer 
  Abdelghani Omari, Chief Financial Officer 
 
 Allenby Capital Limited (Nominated Adviser & Broker) 
 John Depasquale / Jeremy Porter (Corporate   Tel: +44 (0) 20 3328 5656 
  Finance) 
  Tony Quirke / Stefano Aquilino (Equity 
  Sales & Corporate Broking)

About Proteome Sciences plc. ( www.proteomics.com )

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant(R) and TMT(R)MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator(TM) provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDBXBDDUDXDGXB

(END) Dow Jones Newswires

January 02, 2024 02:00 ET (07:00 GMT)

Proteome Sciences (LSE:PRM)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024